New hope for tough bone cancer: experimental drug takes on chemo
NCT ID NCT06935409
First seen Apr 14, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests a new drug called HS-20093 against a standard chemotherapy combination (gemcitabine plus docetaxel) in people with osteosarcoma (bone cancer) that has not responded to at least two prior treatments. About 117 participants aged 12 and older will be randomly assigned to one of the two treatments. The main goal is to see if HS-20093 can delay cancer growth or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital affiliated to Capital Medical University
Beijing, China
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.